Effects of Anti-Retroviral Drugs on Liver and Kidney function among HIV Patients Attending Gitwe District Hospital
Abstract
Background: About 35.3 million people were living with HIV and AIDS worldwide by 2012 up from 33.4 million in 2008 and more than 25 million have died since the first cases were reported in 1981. Sub-Saharan Africa is the worst affected region with an estimated 25 million people (70.8%) of the global total. The population of Sub-Saharan Africa accounts for only 11-12% of the world’s population. The pandemic killed an estimated 1.4 million people in 2012 of which 1.2 million of the cases were from sub-Saharan Africa. The goal of ART is to suppress viral replication and have impaired immunity restored but its major drawback is adverse effects accompanying its use. HAART toxicity has emerged as an important complication and eventually a major reason for ART switch and/or discontinuation. Acute drug toxicities still exist, and although typically not life-threatening, they can affect the quality of life and patients’ willingness to adhere to their treatment regimens.
Aim: the present study aimed to assess the effects of anti-retroviral drugs on liver and kidney function among HIV patients at Gitwe District Hospital.
Methodology: The study used both cross-sectional and retrospective study. A total number of 118 patients participated in the study. Blood samples were examined to assess the effect of HAART on liver and kidney.
Results: Prevalence of abnormal liver and renal analytes in HAART treated were 42.4%.
Conclusion: The study recommended that Gitwe District Hospital and Ministry of Health should establish stringent measures in investigating and screening liver and renal dysfunction by taking blood samples for full hemogram. There are also needs for improvement of diagnostic ability of organs among patients on HAART by the health workers. Routine screening should be encouraged as a prophylactic measure.
Keywords: Anti-Retroviral Drugs, human immune-deficiency virus, Liver function, Kidney function.
Keywords:
Anti-Retroviral Drugs, human immune-deficiency virus, Liver function, Kidney functionDOI
https://doi.org/10.22270/jddt.v15i2.6863References
1. Barrios, A., Rivas, P., Muñoz, J., & Polo, R. Clinical implications of aging in HIV patients on antiretroviral therapy. HIV Medicine, 2021;22(3), 243-255.
2. De Boer, M. G., Boender, T. S., van den Berk, G. E., et al. Liver disease and hepatitis co-infection in HIV patients on antiretroviral therapy. Journal of Hepatology, 2021; 75(5), 1174-1184.
3. Gazzola, L., Raimondo, M., & Monforte, A. D. Mitochondrial toxicity and long-term side effects of antiretroviral therapy. The Lancet HIV, 2018; 5(8), e442-e451.
4. Grinsztejn, B., Nguyen, B. Y., Katlama, C., & Lambert-Niclot, S. The impact of nucleoside reverse transcriptase inhibitors on mitochondrial toxicity in HIV treatment. AIDS, 2021;35(11), 1457-1466.
5. Hernandez-Romieu, A. C., Garg, S., Rosenberg, E. S., et al. Hepatotoxicity and non-nucleoside reverse transcriptase inhibitors. AIDS Research and Human Retroviruses,2019; 35(6), 481-489.
6. Jose, S., Hamzah, L., Campbell, L. J., et al. Tenofovir-associated nephrotoxicity: A longitudinal analysis of kidney function in HIV-positive patients. Journal of Infectious Diseases,2020; 221(9), 1433-1443.
7. Kohli, R., Loomba, R., & Greenbaum, A. Hepatitis B and C co-infection and the progression of liver disease in HIV patients. Hepatology International, 2021; 15(3), 517-530.
8. Kovari, H., Sabin, C. A., Ledergerber, B., et al. Antiretroviral drug-related kidney disease: Incidence and risk factors. Kidney International, 2020; 97(4), 872-879.
9. Li, H., Munoz, F. M., & Verna, E. C. Hepatitis co-infection in HIV-infected individuals and the impact of antiretroviral therapy. Journal of Viral Hepatitis, 2020; 27(11), 1182-1193.
10. Kuehn, B. Rwanda Celebrates Progress Toward HIV Control. JAMA,2019; 322, (19), 1853 1853. https://doi.org/10.1001/jama.2019.18548
11. Andrade, R. J., & Robles‐Díaz, M. Diagnostic and prognostic assessment of suspected drug‐induced liver injury in clinical practice. Liver International,2020; 40 (1), 6-17. https://doi.org/10.1111/liv.14271 PMid:31578817
12. Simon, V., Ho, D. D., & Karim, Q. A. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. The Lancet, 2016;368(9534), 489-504. https://doi.org/10.1016/S0140-6736(06)69157-5 PMid:16890836
Published
Abstract Display: 64 
PDF Downloads: 54 PDF Downloads: 20 How to Cite
Issue
Section
Copyright (c) 2025 ISHIMWE Alain Prudence , MUTABAZI Donatien , GATEMBEZI Tharcisse , HABIYAREMYE Israel , MUKAMANA Marie Louise , NSABIYAREMYE Lauben
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.